Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells

Y Matsumoto1, H Takano, K Kunishio

  • 1Department of Neurological Surgery, Kagawa Medical University, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. mizaya@kms.ac.jp

Insights

This study investigated drug resistance in breast cancer cell lines, finding that increased expression of multidrug resistance-associated protein (MRP) correlates with higher topoisomerase IIalpha levels, suggesting a key mechanism in chemoresistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Topoisomerase II (topo II) inhibitors are crucial in cancer chemotherapy.
  • Understanding mechanisms of drug resistance is vital for improving treatment efficacy.
  • Previous studies on multidrug resistance (MDR)-1 in resistant cell lines showed undetectable levels.

Purpose of the Study:

  • To investigate the molecular mechanisms of resistance to topoisomerase II inhibitors in human breast cancer cell lines.
  • To examine the expression of drug resistance-related genes, including multidrug resistance-associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT), in response to VP-16 and mAMSA.
  • To explore the correlation between gene expression and topoisomerase IIalpha levels in resistant sublines.

Main Methods:

  • Isolation of 50 sublines from four human breast cancer cell lines (MCF-7, T47D, MDA-MB-231, ZR-75B) selected for resistance to VP-16 and mAMSA.
  • Northern blot analysis to assess gene expression of MDR-associated protein (MRP), canalicular multispecific organic anion transporter (cMOAT), and topoisomerase IIalpha (topo IIalpha).
  • Comparative analysis of gene expression levels across different resistant sublines and correlation with parental cell lines.

Main Results:

  • Differential expression of MRP and cMOAT was observed across cell lines; ZR-75B sublines showed high correlation between MRP and cMOAT overexpression.
  • MDA-MB-231 sublines exhibited increased MRP without increased cMOAT.
  • MCF-7 and T47D sublines showed infrequent and low-magnitude increases in MRP or cMOAT. A strong positive correlation was found between MRP expression and topo IIalpha levels across all sublines.
  • No compensatory increase in topoisomerase IIbeta, topoisomerase I, or casein kinase IIalpha was observed.

Conclusions:

  • The expression of drug resistance genes like MRP and transporters like cMOAT varies significantly among breast cancer cell lines.
  • A strong correlation exists between increased MRP expression and elevated topo IIalpha levels in resistant cell lines.
  • These findings suggest that MRP and topo IIalpha modulation are key factors in topoisomerase II inhibitor resistance, with limited evidence for compensatory mechanisms involving other related enzymes.